GlassScriptPhysician profile
Sherry Repass
NPI 1104085414
$2,124.49
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,054 · 2022: $1,071.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $285.25 | 2021-2022 | |
| Amgen INC. | $191.03 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.39 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $151.90 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.34 | 2021 | |
| Lilly USA, LLC | $140.14 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $126.82 | 2021 | |
| Esperion Therapeutics, INC. | $89.46 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $83.62 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $69.59 | 2021 | |
| Arbor Pharmaceuticals, INC. | $66.09 | 2021-2022 | |
| Eisai INC. | $60.95 | 2021 | |
| Amarin Pharma, INC. | $51.59 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $46.07 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $45.09 | 2021-2022 | |
| Pfizer INC. | $41.60 | 2021-2022 | |
| Abbott Laboratories | $38.10 | 2021-2022 | |
| Neos Therapeutics, LP | $35.84 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $35.45 | 2021 | |
| Abbvie INC. | $34.85 | 2022 | |
| Adlon Therapeutics L.P. | $33.48 | 2021 | |
| Amneal Pharmaceuticals LLC | $32.37 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.55 | 2021-2022 | |
| Boston Scientific Corporation | $20.33 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.04 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.58 | 2022 | |
| Upsher-Smith Laboratories LLC | $14.08 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Repass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.